Rituximab or Ocrelizumab? OVERLORD-MS and the Economics of Anti-CD20 Therapy in MS

Bottom Line: In OVERLORD-MS (NEJM, 2026), rituximab was noninferior to intravenous ocrelizumab for preventing new or enlarging T2 lesions from months 6 to 24 in newly diagnosed, treatment-naive adults with active relapsing MS — with similar serious-adverse-event rates but more overall infections. That supports rituximab as a cost-saving anti-CD20 option, at roughly one-sixth the price, where off-label use is acceptable and cost or access is decisive. It does not establish full therapeutic interchangeability, primary-progressive efficacy, pediatric equivalence, or long-term safety parity. Ocrelizumab keeps the advantage where a broad regulatory license, a progressive-MS or pediatric indication, lower immunogenicity, or standardized dosing matter most.

Two monoclonal antibodies deplete the same B cells, by the same mechanism, to treat the same disease. In the United States, in 2021 fourth-quarter Medicare pricing, one runs roughly $12,000 a year; the other, roughly $70,000 (JAMA Neurology, 2023). For more than a decade that arithmetic has powered a quiet natural experiment: while regulators licensed ocrelizumab, much of Scandinavia treated relapsing MS with off-label rituximab and watched what happened. Until this year, the one thing missing was a randomized comparison. OVERLORD-MS now provides it.

Same target, different molecule

Rituximab and ocrelizumab are both intravenous anti-CD20 antibodies that deplete circulating B cells, the intervention that reshaped MS therapeutics after it became clear the disease is not purely T-cell driven. They are not identical proteins. Rituximab is a chimeric antibody (roughly two-thirds human); ocrelizumab is humanized and was engineered specifically to reduce immunogenicity for the repeated dosing that chronic disease demands. The clinically relevant difference is immunogenicity, not infusion tolerability. As a chimeric molecule, rituximab provokes anti-drug (human anti-chimeric) antibodies far more often — roughly a quarter of patients in HERMES developed them by week 48 (14 of 58 completers) — whereas treatment-induced anti-drug antibodies to humanized ocrelizumab appeared in just 0.4% (3 of 807) in the OPERA trials. Infusion reactions, by contrast, are common with both: about 34% of ocrelizumab-treated patients in OPERA had one. The humanized structure buys lower immunogenicity, not freedom from infusion reactions. Both agents deplete circulating B cells rapidly for six to eight months, initially without major immunoglobulin reduction, though repeated dosing can produce hypogammaglobulinemia over time. That lower anti-drug-antibody rate is the strongest mechanistic argument for the more expensive drug, and it is worth keeping in view as the trial data are weighed.

OVERLORD-MS: the head-to-head, at last

OVERLORD-MS (Torkildsen and colleagues, NEJM 2026;395:44–53) was an investigator-initiated, double-blind, double-dummy noninferiority trial conducted at twelve neurology departments in Norway and Sweden. It randomized 218 adults with newly diagnosed relapsing MS to rituximab or ocrelizumab in a 3:2 ratio, every six months for 24 months; 216 were treated (132 rituximab, 84 ocrelizumab). The primary endpoint was the absence of new or enlarging T2 lesions on MRI between month 6 and month 24, and noninferiority was declared if the lower bound of the 95% confidence interval for the between-group risk difference stayed above −10 percentage points.

It did. The model-estimated probability of freedom from new or enlarging lesions was 92.2% with rituximab versus 94.8% with ocrelizumab (observed proportions, 117 of 132 and 78 of 84) — a risk difference of −2.6 percentage points (95% CI, −9.4 to +4.3; P=0.03 for noninferiority), meeting the prespecified margin. The clinical outcomes were similar and uniformly low: annualized relapse rates were 0.09 (rituximab) versus 0.04 (ocrelizumab), with 92% versus 95% of patients relapse-free; confirmed disability progression occurred in 3% versus 7%, and a comparable fraction improved (29% vs 24%). Serious adverse events were essentially equal (8% vs 7%), but infections of any kind were more common with rituximab (82% vs 69%), the great majority of them non-serious. The authors concluded that rituximab was noninferior to ocrelizumab for MRI disease control, with a comparable serious-adverse-event profile.

Two points of interpretation matter before this becomes a talking point. First, noninferior is not equivalent, and neither is superior. The differences were small and internally mixed: the MRI endpoint and the annualized relapse rate nominally favored ocrelizumab, while confirmed disability progression nominally favored rituximab (3% vs 7%) — none of it powered to be conclusive. The honest reading is “no clinically meaningful difference detected,” not “the drugs are identical,” and not that either arm won. Second, the primary endpoint was an MRI surrogate over 24 months — not the long horizon over which MS is ultimately judged. With 216 patients over two years, the trial is not powered to compare rare harms or long-term disability, and its Scandinavian, newly diagnosed cohort (ages 18–60, EDSS 0–4.0) should not be extrapolated uncritically to other populations.

How rituximab earned the comparison

OVERLORD-MS did not arrive in a vacuum. Rituximab is the antibody that first proved the anti-CD20 hypothesis in MS: in the phase 2 HERMES trial (Hauser et al., NEJM 2008), a single course cut gadolinium-enhancing lesions sharply and reduced the proportion of patients relapsing (14.5% vs 34.3% at 24 weeks versus placebo). Every subsequent B-cell therapy, ocrelizumab included, descends intellectually from that result.

The efficacy signal was later reinforced by randomized and real-world Scandinavian data. In RIFUND-MS (Svenningsson et al., Lancet Neurology 2022), a rater-blinded trial of 200 patients, only 3% of rituximab-treated patients relapsed over two years versus 16% on dimethyl fumarate (risk ratio 0.19; P=0.006) — a decisive relapse advantage. A later biomarker analysis of the same cohort added a note of caution worth carrying forward, however: dimethyl fumarate produced the larger fall in serum glial fibrillary acidic protein, and progression independent of relapse activity was numerically more common with rituximab (hazard ratio 3.3; 95% CI 1.1–10). The relapse benefit is real; the long-term progression signal is not entirely one-sided. Swedish registry work (Granqvist et al., JAMA Neurology 2018) exploited a genuine natural experiment — one region used rituximab first-line, another did not — and found rituximab had by far the lowest discontinuation rate and lower relapse and MRI activity than injectables and dimethyl fumarate. The COMBAT-MS program and associated Swedish cost-effectiveness analyses (Piehl, Alping et al., Annals of Neurology 2024) extended that record at population scale — though COMBAT-MS also flagged a counterweight: alongside lower inflammatory activity and higher treatment persistence, rituximab carried a higher rate of serious infections, particularly after switching from another therapy. This is why rituximab became the most-used MS therapy in Sweden despite never being licensed for the indication.

Where ocrelizumab still wins

The case for the branded drug is not merely inertia. Ocrelizumab carries a broad regulatory license — for adult relapsing forms, primary progressive MS, and, since May 2026, relapsing-remitting MS in children 10 and older (≥25 kg) — and with it the reimbursement certainty, manufacturer pharmacovigilance, and medico-legal cover that off-label prescribing lacks. It is also now available as a subcutaneous injection (Ocrevus Zunovo) for adults; OVERLORD-MS, it should be noted, tested the intravenous formulation. Its pivotal OPERA I and II trials (Hauser et al., NEJM 2017) showed a 46–47% lower annualized relapse rate versus interferon beta-1a (0.16 vs 0.29) and reduced 12-week confirmed disability progression (hazard ratio 0.60).

Ocrelizumab is also the only anti-CD20 antibody with a primary progressive MS indication. ORATORIO (Montalban et al., NEJM 2017) was the first trial to slow progression in PPMS (12-week confirmed progression hazard ratio 0.76; P=0.03) — a result achieved, tellingly, by enrolling the younger, inflammatory patients whose benefit had been flagged in the subgroups of rituximab’s own negative PPMS trial, OLYMPUS (Hawker et al., Annals of Neurology 2009). Rituximab has no positive progressive-MS trial; OVERLORD-MS should not be read as licensing its use there. Ocrelizumab also carries the longer paper trail: nine-year extension data (OPERA 9-Year, 2025) show a sustained low annualized relapse rate (0.05) and nearly half of continuously treated patients meeting NEDA-3, with a stable safety profile — a depth of long-term open-label extension follow-up that off-label rituximab, for all its real-world use, does not match. Finally, ocrelizumab’s humanized structure yields far lower rates of anti-drug antibodies and offers standardized fixed dosing — advantages that matter more for some patients than for others.

The economic case — and the WHO’s verdict

The reason this comparison commands attention is price. In fourth-quarter 2021 US pricing, a year’s supply cost roughly $11,759 for rituximab versus $69,949 for ocrelizumab under Medicare (about sixfold), and $5,893 versus $47,671 under Medicaid (about eightfold); the same analysis estimated that using rituximab in place of ocrelizumab could have saved US public payers on the order of $1.9 billion in Medicare and $590 million in Medicaid — about $2.5 billion combined — over 2018 to 2021 (JAMA Neurology, 2023). Formal cost-effectiveness analysis in a middle-income setting (Colombia) found ocrelizumab was not cost-effective against rituximab for relapsing MS. Biosimilar rituximab has widened the gap further.

That evidence has moved policy. In July 2023 the World Health Organization added MS disease-modifying therapies to its Essential Medicines List for the first time, with rituximab included on the strength of its evidence and access profile — an explicit institutional endorsement of a drug used off-label for the disease. For health systems where the choice is between rituximab and no high-efficacy therapy at all, that endorsement is the whole argument.

Where and when to use each

The practical synthesis is not “one drug won.” A decade ago, surveying the coming wave of MS therapies, Brück and colleagues argued for “moving beyond efficacy” — once effectiveness is comparable, the decision should turn on mechanism, safety, immunogenicity, cost, and context (JAMA Neurology 2013). Anti-CD20 therapy is precisely that situation: rituximab and ocrelizumab are close enough on efficacy that the choice legitimately turns on those other axes and on the individual patient. Rituximab is a rational first choice for many newly diagnosed relapsing-MS patients where off-label prescribing is acceptable and cost or access is decisive — publicly funded systems, uninsured or underinsured patients, and low- and middle-income settings where the alternative to off-label rituximab is often no high-efficacy therapy at all. Ocrelizumab is the better choice when its specific advantages are decisive: primary progressive MS, patients in whom immunogenicity or dosing reliability is a particular concern, and systems where a license and manufacturer pharmacovigilance carry real weight. The one framing to avoid is treating the cheaper drug as automatically inferior; OVERLORD-MS says it is not, at least where it has been tested.

Two honest caveats belong in that conversation. Rituximab has been tested less broadly and for less time than ocrelizumab, and its off-label status means there is no manufacturer-run safety-monitoring infrastructure behind it — a legitimate counterweight to the cost argument. And the OVERLORD-MS infection signal, though dominated by minor events, is real and should be disclosed.

Conclusion

OVERLORD-MS closes a decade-long evidence gap with a measured answer: in newly diagnosed relapsing MS, rituximab controls MRI disease activity as well as ocrelizumab over two years, with comparable serious harms and a modest excess of minor infections. It does not make the drugs interchangeable — ocrelizumab still owns the progressive-MS indication, the lower immunogenicity, and the regulatory standing — but it removes the assumption that paying six to eight times more buys better outcomes for the newly diagnosed relapsing patient. The most defensible reading — one consistent with the WHO’s access-first Essential Medicines decision — is that rituximab is a highly effective, dramatically cheaper anti-CD20 antibody that is noninferior where it has been studied. In an era when the cost of MS therapy is itself a barrier to treatment, that is not a small thing to be able to say.